Category Archives: News

Acadeum helps colleges and universities create course-sharing partnerships with like minded-institutions to boost student success, broaden access to educational opportunities, promote curricular innovation and operational efficiencies, and support institution success.

Their impact is driven by their impressive revenue and net income results.

SWAN portfolio company OneSeventeen Media is a certified B-Corp and has been recognized by B-labs as a Best-for-the-World-2021 company.

OneSeventeen Media is focused on marginalized youth, specifically those who aren’t ‘heard’ in our school system. reThinkIt! is a digital mental health platform using chatbot assistants, live chat counselors and an evidence-based ‘early detection’ assessment to help kids 10 to 15 years old better process difficult emotions, understand their own behaviors, and navigate those of others.

Quoting B-Labs: “Within this business community [of 4,000 certified B-Corp companies] operating at the vanguard of the impact economy, those companies that rank in the top 5% of all B Corps on the B Impact Assessment in its size group worldwide for their sustainable business practices are recognized as 2021 Best for the World. .”

OneSeventeen Media was recognized in the categories of Best for Customers and Best for Governance.

Sonnest Has Received over $4M in the Series A Financing to Fund the Initial Evaluation of Electrast™ – the Company’s Voltage Activated Ultrasound Imaging Drug

Sonnest, Inc., a pre-clinical healthcare company developing Electrast™, a voltage-activated ultrasound imaging drug for myocardial perfusion imaging, announced today that the company has raised more than $4M in an oversubscribed Series A financing. The round was led by the SWAN Impact Network, Robin Hood Ventures and the Texas Halo Fund and included a number of doctors, and prominent angel investors. The funds will be used to advance Electrast™ into the clinic, confirm the safety profile of the drug and generate proof-of-principle ultrasound images in human patients similar to the videos created to date in pigs and dogs.

“We are very pleased with the results of our Series A financing because it gives Sonnest the resources the company needs to expand our team, complete GMP manufacturing and advance our innovative product from the animal lab into human patients,” said Peter Boyd, CEO of Sonnest and a serial healthcare entrepreneur who sold his last company to Edwards Lifesciences for $100M upfront and up to $150M in milestone payments. “2020 was a challenging year for everyone but our team continued to advance the development of Electrast™ and I think a lot of investors were excited to participate because they saw how the team performed in the face of significant headwinds.”

Bob Bridge, Executive Director of SWAN Impact Network, said “SWAN is a group of impact investors, and we began evaluating Sonnest in the summer of 2020 based on an introduction by a physician in our network. We were impressed by Sonnest’s cross-functional team of doctors, scientists and business executives, the innovative nature of the company’s technology and what the team was able to accomplish during the pandemic. We were excited to lead the Series A round because we believe that Electrast™ has the potential to cost-effectively improve the diagnosis and monitoring of patients with cardiovascular disease while also lowering risk to the patient by leveraging the power of ultrasound technology.”

The SWAN Impact Network has made two investments in The Brobe, a company providing specialized clothing for post-surgical and other patients. As reported in the Austin American Statesman newspaper and CBS News, The Brobe has launched a line of clothing for the youngest cancer patients.

Harmonic Bionics is redefining neurorehabilitation with intelligent robotic technology designed to maximize patient recovery. The company just closed a $7M preferred stock round.

The company first applied to the SWAN Impact Network in early 2019, and at that time our network felt that the company was not yet ready for their initial funding. And as is our standard practice, SWAN gave the CEO feedback on their application, sharing what we believed to be their strengths and also identifying our concerns. Harmonic Bionics reapplied later in 2019, with a plan that addressed our concerns and SWAN was a major participant in their initial financing, a convertible debt round.

Many of SWAN’s portfolio companies have applied more than once to SWAN and upon reapplication have been funded by our network. Our goal is to be helpful to company applicants who are trying to help the world, and let them know what can make them fundable.

Based upon the conversion of our note in the latest funding round, the valuation of our holding has increased by a factor of 1.9.